ulinastatin

Recombinant proteinexperimental

Ulinastatin is a glycoprotein that is isolated from healthy human urine or synthetically produced and has molecular weight of 25 - 40kDa. It acts as a urinary trypsin inhibitor (UTI). Highly purified ulinastatin has been clinically used for the treatment of acute pancreatitis, chronic pancreatitis, Stevens–Johnson syndrome, burns, septic shock, and toxic epidermal necrolysis (TEN). — Wikipedia

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • acid-stable protease inhibitor
  • miraclid
  • mr 20
  • mr-20 (magnetic powder)
  • mr 20 (magnetic powder) of urinastatin
  • trypsin inhibitor mr-20
  • ulinastatin
  • ulinastatin
  • ulinastatin
  • ulinastatin
  • ulinastatin
  • urinary trypsin inhibitor
  • urinary trypsin inhibitor (68)
  • urinary trypsin inhibitor-like inhibitor (43)
  • urinastatin
  • uti68
  • uti(68)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06966687N/AApr 1, 2025Capital Medical University, Guangzhou Medical University, Huazhong University of Science and Technology, Nanjing Medical University, Sichuan University
NCT05895240Phase 4May 1, 2023Jinnah Postgraduate Medical Centre
NCT05716256N/AFeb 15, 2023Huazhong University of Science and Technology
NCT05534802N/ASep 16, 2022Huazhong University of Science and Technology
NCT05391789Phase 3Jul 31, 2022Fudan University
NCT04711889N/AJan 1, 2021Capital Medical University, Nanjing Medical University
NCT04473144N/AAug 1, 2020Ajou University
NCT04393311Phase 1/Phase 2 (Phase 2)Jun 30, 2020Stanford University
NCT04028024N/AAug 1, 2019Fudan University
NCT03630627Phase 1Aug 21, 2018Parexel, Samsung
NCT03387774Phase 3Jan 30, 2018First People's Hospital of Foshan, Guangzhou Medical University, People's Hospital of Zhongshan, Sun Yat-Sen University
NCT03089957N/AApr 1, 2017Central Hospital, Zibo, Henan Medical University, Peking University, People's Liberation Army of China, Zhengzhou University
NCT02647554Phase 4Dec 1, 2016Techpool Bio-Pharma Co., Ltd., Tsinghua University
NCT02895191Phase 2Aug 1, 2016Bengbu Medical College, Capital Medical University, Guangzhou Medical University, Sichuan University, Techpool Bio-Pharma Co., Ltd., Zhejiang University
NCT03154814Phase 4Jan 1, 2016Konkuk University
NCT02527811Phase 4Apr 1, 2015Fudan University, Guangzhou Medical University, Jiao Tong University, Nanjing Medical University, People's Liberation Army of China, Techpool Bio-Pharma Co., Ltd.
NCT02258906N/AOct 1, 2014Yonsei University
NCT01865266Phase 2/Phase 3 (Phase 3)Jan 1, 2014Fudan University, Jiao Tong University
NCT01894334N/AApr 1, 2013Capital Medical University
NCT01643447N/AMay 1, 2012Eastern Hepatobiliary Surgery Hospital, People's Liberation Army of China
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Capital Medical UniversityAcademic/Hospital4122013
Fudan UniversityAcademic/Hospital4332014
Guangzhou Medical UniversityAcademic/Hospital4042015
Huazhong University of Science and TechnologyAcademic/Hospital4222010
Nanjing Medical UniversityAcademic/Hospital4222010
People's Liberation Army of ChinaGovernment4132011
Techpool Bio-Pharma Co., Ltd.For profit4322010
Sichuan UniversityAcademic/Hospital3032010
Yonsei UniversityAcademic/Hospital3322009
Jiao Tong UniversityAcademic/Hospital2022014
Konkuk UniversityAcademic/Hospital2212008
Sun Yat-Sen UniversityAcademic/Hospital2122010
Tsinghua UniversityAcademic/Hospital2112010
Ajou UniversityAcademic/Hospital1112020
Bengbu Medical CollegeAcademic/Hospital1012016
Central Hospital, ZiboAcademic/Hospital1012017
Changhai HospitalAcademic/Hospital1012011
Chinese Academy of Medical SciencesAcademic/Hospital1112008
Eastern Hepatobiliary Surgery HospitalAcademic/Hospital1112012
First People's Hospital of FoshanAcademic/Hospital1012018
30 organizations
Page 1 / 2